In connection with this abbreviated new drug application, Impax provided notice that its submission includes a paragraph IV certification stating the company believes its product does not infringe US patent, or the patent is invalid or unenforceable.
Amrix is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.